An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs PT 2385 (Primary)
- Indications Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Therapeutic Use
- Sponsors Peloton Therapeutics
- 11 May 2017 According to a Peloton Therapeutics media release, patient dosing has been initiated in this trial.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2017 New trial record